Azam Mohammed Afzal, Tripuraneni Naga Srinivas
Department of Pharmaceutical Chemistry, J. S. S. College of Pharmacy, Ootacamund-643001, Tamil Nadu, India.
Sci Pharm. 2014 Jun 10;82(3):453-81. doi: 10.3797/scipharm.1404-08. Print 2014 Jul-Sep.
Phosphodiesterase 4B (PDE4B) is a member of the phosphodiesterase family of proteins that plays a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) by controlling its rate of degradation. It has been demonstrated that this isoform is involved in the orchestra of events which includes inflammation, schizophrenia, cancers, chronic obstructive pulmonary disease, contractility of the myocardium, and psoriatic arthritis. Phosphodiesterase 4B has constituted an interesting target for drug development. In recent years, a number of PDE4B inhibitors have been developed for their use as therapeutic agents. In this review, an up-to-date status of the inhibitors investigated for the inhibition of PDE4B has been given so that this rich source of structural information of presently known PDE4B inhibitors could be helpful in generating a selective and potent inhibitor of PDE4B.
磷酸二酯酶4B(PDE4B)是磷酸二酯酶蛋白家族的一员,通过控制环磷酸腺苷(cAMP)的降解速率,在调节细胞内cAMP水平方面发挥关键作用。已经证明,这种异构体参与了包括炎症、精神分裂症、癌症、慢性阻塞性肺疾病、心肌收缩力和银屑病关节炎在内的一系列事件。磷酸二酯酶4B已成为药物开发的一个有趣靶点。近年来,已经开发了许多PDE4B抑制剂用作治疗药物。在这篇综述中,给出了用于抑制PDE4B的抑制剂的最新研究状况,以便目前已知的PDE4B抑制剂这一丰富的结构信息来源有助于开发出一种选择性强且有效的PDE4B抑制剂。